These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 1279198

  • 21. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Nájera I, Kohli A, Larder BA.
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [Abstract] [Full Text] [Related]

  • 22. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
    Gao Q, Gu Z, Salomon H, Nagai K, Parniak MA, Wainberg MA.
    Arch Virol; 1994 Sep; 136(1-2):111-22. PubMed ID: 8002779
    [Abstract] [Full Text] [Related]

  • 23. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS, Koerber KL, Pagano JS.
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [Abstract] [Full Text] [Related]

  • 24. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 25. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Nájera R, López-Galíndez C.
    AIDS Res Hum Retroviruses; 1994 Nov 01; 10(11):1479-88. PubMed ID: 7534096
    [Abstract] [Full Text] [Related]

  • 26. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
    Lacey SF, Larder BA.
    Antimicrob Agents Chemother; 1994 Jun 01; 38(6):1428-32. PubMed ID: 7522429
    [Abstract] [Full Text] [Related]

  • 27. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
    Mathez D, Schinazi RF, Liotta DC, Leibowitch J.
    Antimicrob Agents Chemother; 1993 Oct 01; 37(10):2206-11. PubMed ID: 7504908
    [Abstract] [Full Text] [Related]

  • 28. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.
    AIDS; 1998 Jun 18; 12(9):1015-20. PubMed ID: 9662197
    [Abstract] [Full Text] [Related]

  • 29. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
    Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC.
    Antimicrob Agents Chemother; 1997 Apr 18; 41(4):757-62. PubMed ID: 9087484
    [Abstract] [Full Text] [Related]

  • 30. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK, Zhu YQ, Remington KM, Phillips TR, North TW.
    Antimicrob Agents Chemother; 1996 Apr 18; 40(4):953-7. PubMed ID: 8849258
    [Abstract] [Full Text] [Related]

  • 31. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.
    Fitzgibbon JE, Farnham AE, Sperber SJ, Kim H, Dubin DT.
    J Virol; 1993 Dec 18; 67(12):7271-5. PubMed ID: 8230450
    [Abstract] [Full Text] [Related]

  • 32. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul 18; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 33. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.
    Brindeiro R, Vanderborght B, Caride E, Correa L, Oravec RM, Berro O, Stuyver L, Tanuri A.
    Antimicrob Agents Chemother; 1999 Jul 18; 43(7):1674-80. PubMed ID: 10390221
    [Abstract] [Full Text] [Related]

  • 34. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.
    Smith M, Salomon H, Wainberg MA.
    Clin Invest Med; 1994 Jun 18; 17(3):226-43. PubMed ID: 7523016
    [Abstract] [Full Text] [Related]

  • 35. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.
    Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT.
    Antimicrob Agents Chemother; 1992 Jan 18; 36(1):153-7. PubMed ID: 1317143
    [Abstract] [Full Text] [Related]

  • 36. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T.
    J Infect Dis; 1991 Dec 18; 164(6):1075-81. PubMed ID: 1720152
    [Abstract] [Full Text] [Related]

  • 37. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 18; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 38. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
    Gobert JM, Remington KM, Zhu YQ, North TW.
    Antimicrob Agents Chemother; 1994 Apr 18; 38(4):861-4. PubMed ID: 8031060
    [Abstract] [Full Text] [Related]

  • 39. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
    Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC.
    J Infect Dis; 1995 Dec 18; 172(6):1480-5. PubMed ID: 7594706
    [Abstract] [Full Text] [Related]

  • 40. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z, Sönnerborg A, Ayehunie S, Britton S, Strannegård O.
    Antiviral Res; 1992 Oct 01; 19(4):353-9. PubMed ID: 1281393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.